Liang H, Zheng Q-L, Fang P, Zhang J, Zhang T, Liu W, Guo M, Robinson CL, Chen S-B, Chen X-P et al..  2017.  Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.. Sci Rep. 7:40361.

Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K et al..  2017.  VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.. Oncogene. 36(1):1-12.

Zloza A, A Palucka K, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA et al..  2017.  Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.. J Immunother Cancer. 5(1):77.

Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al..  2016.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.. Genome Biol. 17(1):174.

McKenney ASophia, Levine RL.  2013.  Isocitrate dehydrogenase mutations in leukemia.. J Clin Invest. 123(9):3672-7.